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Background: A common side effect of oxaliplatin is peripheral neurotoxicity. Oxidative stress to dorsal root
ganglion (DRG) may be one of important pathogenic mechanisms. Green tea contains four polyphenol catechins,
which are known to be potent antioxidants. The present work is aimed to determine whether green tea extracts
have neuroproective or palliative effects on neurotoxicity symptoms induced by oxaliplatin.
Methods: We conducted behavioral tests including sensory and thermal thresholds, an electrophysiological study,
and TUNEL staining to assess neurotoxicity during the experimental period using animal models.
Results: A total of 14 adult rats were randomly allocated into two groups. Oxaliplatin (4 mg/kg) with or without
green tea (300 mg/kg orally once daily) was administered intraperitoneally twice per week for 6 weeks. At 4 and
6 weeks after oxaliplatin administration, sensory threshold values were significantly decreased and at 6 weeks after
oxaliplatin administration, thermal threshold values were significantly increased in oxaliplatin-treated rats compared
with those in rat treated with oxaliplatin and green tea extracts. The electrophysiological assessment, including
sensory nerve conduction and H-reflex-related sensory nerve conduction velocity, revealed no significant changes
in the two groups. TUNEL staining showed no significant difference in the number of apoptotic-featured cells
between the two experimental groups in the DRG or peripheral nerves, but the number of apoptotic-featured cells
in DRG was higher than that in sciatic nerves within each group.
Conclusions: Green tea extracts may be a useful adjuvant to alleviate sensory symptoms after oxaliplatin
administration, such as allodynia, but did not prevent morphometric or electrophysiological alterations induced by
oxaliplatin.
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Neurotoxicity is a common adverse effect associated
with antineoplastic agents. Of these agents, oxaliplatin
has been commonly used in clinical practice to treat
various cancers of the gastrointestinal tract. A common
and dose-limiting side effect of oxaliplatin is peripheral
neurotoxicity (PN), which is known to be cumulative [1].
At cumulative doses that reach 800 mg/m2, the occur-
rence of neurotoxicity is highly likely. A total neuropathy
score ≥ grade 3 PN occurs in 15% of cases after cumula-
tive doses of 750-850 mg/m2 and in 50% of cases after a
total dose of 1170 mg/m2 [2].* Correspondence: koyoonho@catholic.ac.kr
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reproduction in any medium, provided the orOxaliplatin treatment induces an acute neurotoxicity,
characterized by a rapid onset of cold-induced distal
dysesthesia and a chronic sensory peripheral neuropathy
[1]. The clinical similarity between the acute oxaliplatin-
induced PN symptoms, such as transient paresthesia and
dysesthesia in the perioral area, and conditions caused
by impairment of neuronal ion channels suggests that
oxaliplatin interacts with ion channels located in the cel-
lular membrane [3] or induces alteration in voltage-
gated sodium (Na+) channel function [4]. On the other
hand, the chronic, sensory, oxaliplatin-induced PN may
be induced by decreased cellular metabolism and axo-
plasmatic transport secondary to the accumulation of
platinum compounds in dorsal root ganglia (DRG) cells
[5], by the impairment of cellular mitochondrial oxygen
consumption [6], or by the prolonged activation of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in sensory nerve cells via excess Ca2+ influx [7].
Antineoplastic agents are known to produce oxidative
stress, reduce the total radical-trapping capacity of blood
plasma, and decrease plasma levels of antioxidants [8].
Reactive oxygen species modulate Na+ channel activity
[9], a class of ion channels that has been suggested to
enhance nociceptor activity in patients with acute
oxaliplatin-induced PN [10]. Moreover, the evidence that
DRG oxidative stress may be an important pathogenetic
mechanism for chronic toxicity is increasing [11].
Dose-limiting neuropathies may require clinicians to
adjust chemotherapeutic doses. An ideal approach is to
prevent or minimize neuropathy symptoms and not to
reduce the efficacy of chemotherapeutic agents against
tumors. Though an effective treatment of established
chemotherapy-induced PN has not been found, many
prevention and treatment strategies have been suggested,
including amifostine, acetyl-L-carnitine, and antioxi-
dants, such as vitamin E, vitamin C, β-carotene, and
glutathione [12]. Green tea contains four polyphenol
catechins: gallocatechin, epigallocatechin, epicatechin,
and epigallocatechin-3-gallate (EGCG) [13]. Because
polyphenol catechins are known to be potent antioxi-
dants, catechins have been investigated for their ability
to prevent cancer development and chemotherapy-
induced toxicities [14]. Platinum antineoplastic agents
have been shown to induce a fall in plasma antioxidant
levels, due to oxidative stress in human studies, and sup-
plementation with antioxidants has shown a protective
effect against cisplatin-induced renal toxicity and ototox-
icity in animal studies [15]. Thus, based on the above,
we conducted an animal experiment to determine
whether green tea extracts have neuroproective or pallia-




Experiments were performed on 301 ± 7 g adult male
Sprague-Dawley rats. Animals were housed 3 per cage in
a temperature- and humidity-controlled environment
under a 12/12-h light/dark cycle. Food and water were
freely available. All experimental procedures were
approved by the Animal Experimental Committee of the
Catholic University of Korea. All efforts were made to
minimize the number of animals used and their
suffering.
Experimental design and protocol
In total, 14 animals were randomly allocated into two
groups of seven animals. In Group I (n= 7), oxaliplatin
(4 mg/kg) mixed with 0.9% lactose was administered
intraperitoneally twice per week for 6 weeks. In Group II(n= 7), in addition to oxaliplatin (4 mg/kg), green tea
extracts (Zhejiang Shaoxing Dongling Health Food Co.,
Ltd; Zhejiang, China), containing 60 mg/kg of EGCG,
was administered orally once daily for 6 weeks. We mea-
sured weights weekly and conducted behavioral and
electrophysiological tests before oxaliplatin administra-
tion, at 2, 4, and 6 weeks on all experimental animals. At
6 weeks, DRG and sciatic nerves were harvested from all
experimental animals.
Behavioral studies
Assessment of sensory threshold values in hind paws
This test was performed only during the daytime portion
of the circadian cycle. Rats were individually placed in a
cage with a wire-mesh bottom. They were allowed ap-
proximately 15 min for behavioral accommodation,
which ended when cage exploration and major grooming
activities ceased. We tested the mid-plantar portion of
only the right hind paw before the electrophysiological
test to avoid the traumatic effect of the insertion of nee-
dle electrodes.
The hind paws were first touched with 5.88 monofila-
ment (force gram : 60 gram) of a series of von Frey hairs
with logarithmically increasing levels of stiffness
(Touch-Test Sensory Evaluators, Stoelting Co., Wood
Dale, IL, USA). These were presented perpendicular to
the plantar surface with sufficient force to cause slight
buckling against the paw, and were then maintained in
that position for approximately 6-8 s. Stimuli were pre-
sented at intervals of several seconds to allow time for
the resolution of the behavioral responses to previous
stimuli. A positive response was noted if the tested paw
was withdrawn sharply during 5 of the 10 trials. Flinch-
ing immediately upon removal of the hair was also con-
sidered a positive response if flinching occurred during 5
of the 10 trials. Ambulation was considered an ambigu-
ous response, and the stimulus was repeated in such
cases. If a positive response was noted, we selected the
one-step lower weight monofilament and, to reconfirm
the positive response, the two-step lower weight mono-
filament was used. If a negative response was noted, we
selected the next higher weight monofilament, 6.1
monofilament, but we used 6.1 monofilament only,
being afraid of the trauma. The tests were twice repeated
on two different daytime by one examiner, and the force
grams of monofilaments were averaged.
Assessment of thermal threshold values in the tail
A Tail-Flick Analgesia Meter (Harvard Apparatus,
Holliston, MA, USA) was used to conduct tail-flick tests
within the chamber. A beam of radiant heat (a single,
fixed aperture) was focused on the underside of the mid-
dle third of the rat’s tail. The latency between exposure
to the radiant heat source and movement of the tail
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tensity was set at 50% of maximal intensity, and maximal
exposure to the radiant heat stimulus was 5 s (“cutoff
time”) to avoid burn injuries. Since baseline latencies
vary between animals, we use the percentage of maximal
possible effect (%MPE) as parameter of thermal thresh-
old values. A percentage of maximal possible effect
(%MPE) is derived from these measures
%MPE ¼
latency sð Þ following oxaliplatin administration
latency sð Þ under baseline conditions
cutoff time 5 sð Þ
latency sð Þ under baseline conditions
Electrophysiology
All measurements were performed by one electrodiag-
nostic expert while the animals were under general
anesthesia (Zoletile, Virvac, France; 30 mg/kg, intraperi-
toneal injection). Skin temperatures were manipulated
using an infrared lamp, and the temperatures of the tail,
foot, and leg were checked with an infrared thermom-
eter and ranged between 29 and 30°C.
To assess nerve conduction velocity related to the H-
reflex, the left hindlimbs were secured to the long axis
of the body at an angle of 30-45°. A monopolar EMG-
recording electrode, which served as the active electrode
for purposes of recording, was inserted between the left
fourth and fifth digits, parallel to the long axis of the left
foot. The reference electrode was inserted into the fifth
digit of the same foot, and a ground electrode, using a
disposable surface electrode, was placed on the tail. The
tibial nerve was stimulated through a monopolar cath-
odal stimulating electrode, which was inserted in the left
ankle near the left tibial nerve and in the left hip near
the sciatic nerve at the sciatic notch. The anode was
placed 5 mm proximal to the cathode. The H-reflex-
related sensory nerve conduction velocity (SNCV) was
calculated using the latencies of the H-responses at both
stimulation points and the distance between the two
stimulation points (the sciatic notch and ankle in the
gently stretched paw).
To record the sensory nerve action potentials evoked
in the tail nerve, we used an antidromic conduction
technique. Two subdermal needle electrodes were
located in the tail; the active electrode was inserted in
the proximal part, and the reference electrode was
inserted in the distal part of the tail. The distance be-
tween the stimulating and recording electrodes was
7 cm, which was measured on the skin. The nerves were
stimulated via monopolar needles by a single pulse deliv-
ered by an electrical stimulator with an intensity of 1-
2 mA, a duration of 0.1 ms, and a frequency of 1 Hz
(Synergy, Medelec, Ltd., Old Woking, England).TUNEL method
The TUNEL method was used to observe apoptotic cells
induced by chemotherapy using an in situ apoptosis de-
tection kit (Takara Bio, Inc., cat. # MK500). Sciatic
nerves were harvested 0.5 cm away from the electrode
stimulation at the ankle to avoid the possibility of nerve
trauma, and four DRG (bilateral fourth and fifth lumbar
level) were harvested. Tissues were made into paraffin
bocks. Paraffinized nerve tissues were deparaffinized
using xylene, 100% ethanol, 90% ethanol, and 80% etha-
nol, in order, for 5 min, washed with flowing water for
2 min, and immersed in distilled water. After proteinase
K (20 μg/mL) was applied, tissues were left at room
temperature for 15 min and washed with phosphate-
buffered saline. A total of 50 μL of labeling reaction mix-
ture (5 μL TdT enzyme+ 45 μL labeling safe buffer) was
applied to slides and incubated in a 37°C humidified
chamber for 90 min. Apoptotic cells were viewed and
counted by at × 200 with a fluorescence microscope at
three different points in each tissue sample.
Statistical analyses
Values are expressed as means ± SD. Normality of distri-
bution was tested with the Shapiro-Wilk test; for thresh-
olds in which the distribution was not within acceptable
limits of normality (P < 0.05), we used the nonparametric
equivalent (the Mann-Whitney test). All tests were one-
tailed, and significance was set at P < 0.05.
Results
Assessment of general toxicity
Before oxaliplatin administration, the weight of Group I
was 303 ± 5 g and that of Group II was 299 ± 8 g; these
were not statistically significant different (P= 0.25). The
weights of the rats in Group I increased from 303 ± 5 g
to 338 ± 15 g, and the weights of the rats in Group II
increased from 299 ± 8 g to 352 ± 20 g during the course
of the experiment (Figure 1). However, no statistically
significant difference was found between the two groups
throughout the 6-week experimental period in terms of
body weight (P > 0.05). In Group I, two rats died at
4 weeks after the start of the experiment, and in Group
II, one died at 5 weeks after the start of the experiment.
Behavioral studies
Assessment of sensory threshold values in hind paws
The sensory threshold test in the right hind paw was
conducted before oxaliplatin administration and at
weeks 2, 4, and 6 after oxaliplatin administration. Before
oxaliplatin administration and at week 2 after oxaliplatin
administration, there was no significant difference in
sensory thresholds between the two groups (P= 1.0 and
P= 0.39, respectively). However, at 4 and 6 weeks after
oxaliplatin administration, a significant difference in
Figure 1 The assessments of general toxicity. No changes in weight of rats were observed after oxaliplatin administration between the
control and green tea extracts treated groups (p > 0.05).
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found; the mean sensory thresholds of Group II
(19.9 ± 6.7 g and 20.6 ± 15.9 g, respectively) were higher
than those of Group I (9.5 ± 5.9 g and 10.6 ± 7.2 g, re-
spectively; P= 0.01 and P= 0.01, respectively; Figure 2).
Assessment of thermal threshold values in the tail
At 2 and 4 weeks after oxaliplatin administration, no sig-
nificant difference was found in the mean% MPE be-
tween Groups I and II (P > 0.05). However, at 6 weeks
after oxaliplatin administration, the mean% MPE ofFigure 2 The assessment of sensory thresholds using touch-test sens
there was no significant difference in sensory thresholds between the two
administration, the mean sensory thresholds of Group II with green tea(300
I without green tea(P< 0.05). * P< 0.05.Groups I and II were 8.1 ± 3.0 and 5.2 ± 2.5, respectively,
which showed the increased thermal threshold values in
Group I when compared to the Group II taking green
tea extracts (P< 0.05, Figure 3).
Neurophysiological evaluation
Sensory nerve conduction in the tail and the H-reflex-
related SNCV were determined in all experimental
animals at baseline and at 2, 4, and 6 weeks after oxali-
platin administration. At baseline, the peak latency, amp-
litude, and H-reflex-related SNCV were 2.9 ± 0.3 ms,ory evaluators. Before and at 2 weeks after oxaliplatin administration,
groups (P > 0.05). However, at 4 and 6 weeks after oxaliplatin
mg/kg orally once daily) were statistically higher than those of Group
Figure 3 The assessment of thermal thresholds using tail-flick analgesia meter. Effects of green tea extracts on tail flick test after oxaliplatin
administration indicated by maximal possible effect (%MPE) (mean± SD), which showed the mean%MPE of Group II with green tea(300 mg/kg
orally once daily) were statistically lower than those of Group I without green tea at 6 weeks after oxaliplatin administration (P< 0.05). * P< 0.05.
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I and 2.9 ± 0.2 ms, 39.2 ± 10.0 μV, and 50.8 ± 6.7 m/s, re-
spectively, in Group II; there was no significant differ-
ence between the two groups (P > 0.05). At 2, 4, and
6 weeks after oxaliplatin administration, no significant
difference was observed in the mean peak latency, ampli-
tude, or H-reflex-related SNCV between the two groups
(P > 0.05, Tables 1 and 2).
TUNEL staining
The mean numbers of apoptotic-featured cells in DRG
and sciatic nerves were 10 ± 3 and 2 ± 1 in Group I and
8 ± 2 and 2 ± 1 in Group II, respectively; no statistically
significant difference was seen between the two groups
(P > 0.05, Figure 4). However, the number of apoptotic-
featured cells in DRG was higher than that of sciatic
nerves in Groups I and II (P= 0.01, Figure 5).
Discussion
The present study investigated the preventive role of
green tea extract, containing antioxidants, in oxaliplatin-
induced PN using a rat model. The findings showed thatTable 1 Sensory nerve conduction study in tail of rats
Initial
Peak Latency (msec) Group I 2.91 ± 0.27
Group II 2.94 ± 0.21
Amplitude (μV) Group I 37.16 ± 10.55
Group II 39.20 ± 9.96green tea extracts alleviated mechanical allodynia or
decreased thermal response after oxaliplatin administra-
tion, but did not prevent morphometric or electro-
physiological alterations induced by oxaliplatin. Green
tea extracts may induce a mild neuroprotective or pallia-
tive effect in a certain period time of sensory oxaliplatin-
induced PN.
In this study, we observed that neurotoxicity symp-
toms in experimental Group II, which received oxalipla-
tin and green tea extracts, was significantly alleviated in
the sensory threshold test using Von Frey hairs at 4 and
6 weeks (P= 0.01) and thermal threshold test at 6 weeks
(P= 0.048) after oxaliplatin administration, compared
with experimental Group I which received oxaliplatin
alone. Based on the findings of this animal experiment,
we hypothesize that the damaging properties of free
radicals may have an effect for a certain period of time
of oxaliplatin-induced sensory neuropathy. Findings
reported by various investigators are consistent with this.
Joseph et al. [16], in an experimental study with rat
models, observed that oxaliplatin acts on nociceptors to
induce oxidative stress-dependent acute peripheral2 weeks 4 weeks 6 weeks
2.96 ± 0.20 2.88 ± 0.20 2.76 ± 0.17
2.83 ± 0.22 2.74 ± 0.11 2.64 ± 0.14
38.69 ± 6.29 37.77 ± 7.30 24.50 ± 6.81
32.90 ± 8.15 32.57 ± 13.96 23.69 ± 11.20
Table 2 H-reflex related sensory nerve conduction velocity in rats
Initial 2 weeks 4 weeks 6 weeks
Group I 49.9 ± 10.3 m/sec 49.6 ± 7.3 m/sec 48.3 ± 6.7 m/sec 50.7 ± 8.2 m/sec
Group II 50.8 ± 6.7 m/sec 51.9 ± 12.5 m/sec 48.9 ± 13.8 m/sec 46.3 ± 12.8 m/sec
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ministration of antioxidants, such as acetyl-L-carnitine,
alpha-lipoic acid, and vitamin C, markedly inhibited
oxaliplatin-induced hyperalgesia. A recent report
demonstrated that epigallocatechin gallate, a major poly-
phenolic catechin present in green tea, induces heme
oxygenase-1 expression in cultured rat neurons, possibly
by activation of the transcription factor Nrf2, and by this
mechanism is able to protect against oxidative stress-
induced cell death [17].
In the late course of oxaliplatin treatment, however, it
continues to accumulate in nerve tissues and inevitably
induces chronic toxicity. In this study, green tea extracts
did not prevent morphometric or electrophysiological
alterations by oxaliplatin. This indicates that a patho-
genic mechanism other than free radical injury, includ-
ing apoptosis of DRG cells [5], the impairment of
cellular mitochondrial oxygen consumption [6], or pro-
longed activation of voltage-gated Na+ channels, which
leads to excess Ca2+ influx [7], may also be significantly
involved in chronic oxaliplatin-induced PN. Additionally,
the relationship between acute manifestations and the
development of chronic manifestations of oxaliplatin-
induced PN has not been fully elucidated. A recent study
reported that acute modulation of Na+ channel proper-
ties in both motor and sensory axons influences the final
severity of oxaliplatin-induced PN [4]. Additionally,Figure 4 The comparison of apoptotic-featured cells between the two
were not found in dorsal root ganglia or sciatic nerve between two group
(P > 0.05).recent studies suggest that reactive oxygen species likely
have a role in the link between acute and chronic mani-
festations [11].
No significant alteration in the nerve conduction study
was found during oxaliplatin treatment, which may be
explained by the fact that the main pathological changes
in oxaliplatin-induced neuropathy occur predominantly
in DRG[18] not sciatic nerves. Additionally, there was
not enough to provoke histological alterations that could
be detected as electrophysiological abnormalities in per-
ipheral nerves, because electrophysiological parameters
usually change with Wallerian degeneration of a given
peripheral nerve. Contrary to our electrophysiological
findings, an experimental animal study that evaluated
the protective role of acetyl-l-carnitine in paclitaxel- and
cisplatin-induced neurotoxicity showed somewhat differ-
ent results: SNCV was significantly reduced compared
with that in the control group in both cisplatin and cis-
platin + acetyl-l-carnitine groups (P< 0.001 for both
groups). The difference, however, was significantly less
marked in the cisplatin + acetyl-l-carnitine group (con-
trol group (mean ± SD) 41.1 ± 3.0 m/s; cisplatin group
27.8 ± 1.9 m/s; and cisplatin + acetyl-l-carnitine group
33.4 ± 2.8 m/s), and the difference between the two
groups of cisplatin-treated rats was significantly in favor
of acetyl-l-carnitine cotreatment [19]. However, a study
of oxaliplatin-induced neurotoxicity in humans showedgroups. The statistical significances of the number of apoptotic cells
s, which were harvested at 6 weeks after oxaliplatin administration
Figure 5 The comparison of apoptotic-featured cells between DRG and sciatic nerve in both groups. TUNEL staining shows the increased
number of apoptotic-featured cells in dorsal root ganglia of two groups (A. Group I, B. Group II, White arrow), but apoptotic-featured cells were
not easily found in sciatic nerve of two groups(C. Group I, D. Group II), x 200 magnification. The white arrow marks indicate the apoptotic-
featured cells.
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duction study results was a low-amplitude sensory nerve
action potential (SNAP) in all eight symptomatic sub-
jects. This reduction in sural SNAP amplitude was asso-
ciated with a minor decrease in conduction velocity in
symptomatic patients, although the mean sural nerve
conduction velocity was not significantly altered [10].
These differing electrophysiological findings may be due
to the temperature effect on the sensory nerve conduc-
tion study. All neurophysiological determinations were
performed under standard conditions in a temperature-
controlled room in an experimental animal study of
reference articles [20], which caused critically false nerve
conduction study results. The skin temperature, not the
room or core temperature, is the most profound factor
in nerve conduction studies. Because the general condi-
tion of animals that have received chemotherapy is con-
tinually aggravated, it is very difficult to maintain the
skin temperature at an appropriate level (30 - 32°C)
under standard conditions in a temperature-controlled
room. Thus, lowering the temperature of a nerve has a
direct effect on the nerve’s action-potential-generating
mechanism at the nodes of Ranvier. Under these cir-
cumstances, the amplitude of the action potential is also
increased, and the latency and conduction velocity are
prolonged. The main change in nerve conduction study
results in animal chemotherapeutic studies seems to bedelayed latency and conduction velocity, not decreased
amplitude. In this study, we used an infrared heat lamp
to raise the surface temperatures of the tail, foot, and
leg, to 29 - 30°C.
A nerve conduction study may be a useful tool for
understanding the pathophysiology of neuropathies or
for clinical monitoring of neurotoxicity in patients who
undergo chemotherapy, but it is not thought to be a sen-
sitive tool for acute oxaliplatin neurotoxicity, considering
the technical differences between expert and non-expert
practitioners. Further, the variability in the measurement
of amplitudes of sensory action potentials is substantially
greater than the variability in the measurement of ampli-
tudes of motor action potentials. The conventional nerve
conduction study lacks the sensitivity, while there is a
report that sensory abnormalities in an axonal excitabil-
ity test occurred prior to a significant reduction in the
compound sensory amplitude and the development of
neuropathy; additionally, excitability changes occurred
before clinically significant neurotoxic symptoms. This
suggests that assessment of sensory excitability para-
meters may provide a sensitive biomarker of severity for
oxaliplatin-induced neurotoxicity [21].
Increasing interest in the oxidative stress induced by
chemotherapeutic agents and its role in the mechanism
of adverse effects has recently been addressed. To date,
several antioxidant agents have been tested for their
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mized, double-blind, placebo controlled trial, glutathione
effectively reduced oxaliplatin-induced PN clinically and
electrophysiologically without reducing the clinical activ-
ity of oxaliplatin [22]. Alpha-lipoic acid has effectively
reduced the severity of this dose-limiting oxaliplatin-
related side effect in 15 patients with advanced colorec-
tal cancer who were treated with an oxaliplatin-based
regimen and experienced a ≥ grade 2 oxaliplatin-induced
PN [23]. Pace et al. demonstrated that supplementation
with vitamin E decreased the incidence (30.7% vs. 85.7%;
P < 0.01) and severity (2 vs. 4.7; P < 0.01) of PN in a com-
parison of 27 patients receiving cisplatin chemotherapy
with vitamin E with those receiving only cisplatin
chemotherapy [15]. The effects of green tea on chemo-
prevention have been investigated. There is a report that
administration of doxorubicin alone decreased tumor
weight by 25% compared with the control level, whereas
the addition of green tea markedly reduced the tumor
weight, to 37% of the control level, and significantly
enhanced the doxorubicin inhibitory effect on tumor
growth, 2.5-fold. Green tea, theanine, and caffeine in
combination with doxorubicin did not increase the
doxorubicin concentration in the heart or liver of
tumor-bearing mice [24]. Based on the fact that green
tea, which has antioxidative properties, has a positive ef-
fect on cancer chemotherapy, we expect that the neuro-
toxicity of oxaliplatin could be minimized.
Conclusions
In summary, considering that oxaliplatin administration
produces an acute “functional” channelopathy of axonal
Na+ channels, the findings of the present study suggest
that green tea extracts seem to alleviate functional chan-
nelopathy, based on results at 4 and 6 weeks after oxali-
platin administration, although objective parameters
such as electrophysiological and histological findings
were apparently unaffected. Thus, even though they
seem to have temporary effect on neurotoxicity, green
tea extracts may be a useful adjuvant to alleviate sensory
symptoms in the early stages of neurotoxicity in clinical
settings.
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